Here’s what you need to know:
1. twoXAR develops biomedical software, which evaluates drug candidates through dataset analysis. These evaluations can be used to prioritize drug candidates prior to clinical testing.
2. In this collaboration, twoXAR will use its software to make predictions about drug candidates targeting hepatocellular carcinoma, a form of liver cancer.
3. The drug candidates that twoXAR determines to be high-priority will be put through preclinical studies, conducted by researchers at the Asian Liver Center.
More articles on gastroenterology and endoscopy:
AGA hosts advocacy day to encourage MACRA oversight: 3 notes
Dr. Milena Bogunovic receives $100k award for IBD research: 3 notes
Galmed Pharmaceuticals names Dr. Liat Hayardeny chief scientific officer: 3 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.